MYCN and Familial prostate cancer: Furthermore, EZH2 and SUZ12 interact with N-MYC through MB III in castration-resistant prostate carcinoma (CRPC), leading to abrogation of androgen receptor signaling and consequently driving progression to neuroendocrine prostate cancer (NEPC), the aggressive subgroup of late-stage prostate cancer [103].